Olverembatinib (HQP1351)
HQP1351SJ0003
Ascentage Pharma · Phase 1 · Recruiting · Enrollment 100
| Arm | Reported safety |
|---|---|
| Olverembatinib 30 to 50 mg every other day | n/r |
A count stays a count. This page does not turn a count into a percent.
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
Olverembatinib (HQP1351)
Ascentage Pharma · Phase 1 · Recruiting · Enrollment 100
| Arm | Reported safety |
|---|---|
| Olverembatinib 30 to 50 mg every other day | n/r |
A count stays a count. This page does not turn a count into a percent.